Propel Bio Management LLC Raises Stock Position in Compass Pathways PLC Sponsored ADR $CMPS

Propel Bio Management LLC increased its holdings in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 69.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 861,778 shares of the company’s stock after purchasing an additional 351,778 shares during the quarter. Compass Pathways makes up 5.1% of Propel Bio Management LLC’s investment portfolio, making the stock its 7th biggest holding. Propel Bio Management LLC’s holdings in Compass Pathways were worth $5,946,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in CMPS. Advisory Services Network LLC bought a new position in Compass Pathways during the 3rd quarter worth approximately $41,000. BIT Capital GmbH bought a new position in Compass Pathways during the 3rd quarter worth approximately $54,000. Northeast Financial Consultants Inc bought a new position in Compass Pathways during the 2nd quarter worth approximately $59,000. Raymond James Financial Inc. raised its holdings in Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after purchasing an additional 6,228 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC bought a new position in Compass Pathways during the 4th quarter worth approximately $104,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

Shares of CMPS opened at $12.11 on Friday. Compass Pathways PLC Sponsored ADR has a 12-month low of $2.25 and a 12-month high of $14.76. The business’s fifty day moving average is $8.99 and its 200 day moving average is $7.39. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.63 billion, a P/E ratio of -3.84 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Sell-side analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on CMPS shares. HC Wainwright restated a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Maxim Group raised their price objective on shares of Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. B. Riley Financial began coverage on shares of Compass Pathways in a research report on Friday, April 24th. They set a “buy” rating and a $17.00 price objective for the company. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Finally, Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Pathways currently has an average rating of “Moderate Buy” and a consensus price target of $21.36.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.